BMS warning letter cites plant in familiar Puerto Rico; WHO tries API prequalification;

> Bristol-Myers Squibb has earned an FDA warning for its Puerto Rico manufacturing plant. Warning letter

> The WHO has begun a pilot prequalification program using selected APIs for HIV treatments, anti-malarials and anti-tuberculosis products. Article

> ATMI has opened a Chinese manufacturing facility with partner Austar, a Hong Kong-based service provider. ATMI release

> PPD and Bend Research will collaborate on formulation development, analytical testing and clinical supplies manufacturing. PPD release 

> Liberia has established a regulatory authority to address counterfeit and substandard drugs. Article

> Unilife has secured funding for construction of its headquarters and manufacturing facility in York, PA. Unilife release

> Recipharm will scale-up the manufacturing of DuoCort's tablets for treatment of Addison's disease. Article

> Lonza is seeing increased capacity utilization in custom manufacturing but says regulatory strictness is creating volatility. Item

> UK contract manufacturer SCM Pharma is set to open its first US office after appointing Thomas Puskar its North American business development manager.  SCM release

> A proposal for drugmaker support of an unwanted drug disposal program in San Francisco has drawn industry opposition. Article

> Laureate will manufacture AVEO's AV-201, a monoclonal antibody treatment intended cancer. Laureate release

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.